Recently, ABT-263 has been widely used as an orally bioavailable inhibitor of prosurvival BCL-2 proteins in many antitumor therapies by targeting tumor cell apoptosis and inhibiting cell proliferation (Gandhi et al., 2011; Wang et al., 2016; Froehlich et al., 2019). Here, BCL2 is linked to neoplasm.